Prem Lachman's questions to Legend Biotech Corp (LEGN) leadership • Q4 2024
Question
An analyst from MAXIMUS Capital sought clarification on the quarterly growth outlook for the year and comfort with consensus estimates. He also asked about market dynamics versus a new competitor in 2026 and how Legend plans to maintain its market share.
Answer
An Unknown Executive confirmed the outlook for sequential growth each quarter, with a significant step-up in Q2, and expressed confidence in doubling commercial supply. Regarding 2026 competition, the executive stated that by then, the overwhelming majority of revenue will be from the second- to fourth-line setting, where CARVYKTI is well-positioned with unmatched CR rates and an overall survival benefit, which they expect to be added to the label.